Clinical and therapeutic relevance of PIM1 kinase in gastric cancer

Gastric Cancer

Volumn 15, Issue 2, 2012, Pages 188-197

  Yan, Benedict ^a   Yau, Ee Xuan ^b   Samanta, Sanjay ^c   Ong, Chee Wee ^b   Yong, Kol Jia ^b   Ng, Lai Kuan ^a   Bhattacharya, Bhaskar ^b   Lim, Kiat Hon ^d   Soong, Richie ^b   Yeoh, Khay Guan ^a   Deng, Niantao ^e   Tan, Patrick ^e   Lam, Yulin ^c   Salto Tellez, Manuel ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Amplification; Gastric cancer; PIM1; Targeted therapy

Indexed keywords

1 [3 [6 (CYCLOPROPYLMETHYLAMINO)IMIDAZO[1,2]PYRIDAZIN 3 YL]PHENYL]ETHANONE; ANTINEOPLASTIC AGENT; K 00135; MESSENGER RNA; PROTEIN KINASE PIM 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CELL GROWTH; CELL VIABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PIM1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; STOMACH CANCER; STOMACH EPITHELIUM;

AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-PIM-1; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84861530026     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0097-2     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008;23:351-65. (Pubitemid 351342074)
3. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101:1306-7.
4. Padma R, Nagarajan L. The human PIM-1 gene product is a protein serine kinase. Cancer Res. 1991;51:2486-9.
5. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37:141-50. (Pubitemid 14079845)
6. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006;38:430-43. (Pubitemid 41821890)
7. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68:5076-85.
8. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571:43-9. (Pubitemid 38992921)
9. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008;283:3349-56.
10. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA. A role for polyploidy in the tumorigenicity of Pim-1- expressing human prostate and mammary epithelial cells. PLoS ONE. 2008;3:e2572.
11. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, et al. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003;63:8079-84. (Pubitemid 37549449)
12. Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, et al. Structural analysis identifies imidazo[1, 2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007;67:6916-24. (Pubitemid 47105539)
13. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, et al. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003;23:167-78. (Pubitemid 36358514)
14. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, et al. Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia. 2006;20:539-42. (Pubitemid 43291765)
15. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol. 2006;59:285-8. (Pubitemid 43344891)
16. Beier UH, Weise JB, Laudien M, Sauerwein H, Gorogh T. Overexpression of Pim-1 in head and neck squamous cell carcinomas. Int J Oncol. 2007;30:1381-7.
17. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007;6:163-72. (Pubitemid 46206679)
18. Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett. 2007;17:1679-83. (Pubitemid 46274341)
19. Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem. 2008;51:1972-5. (Pubitemid 351438879)
20. Tong Y, Stewart KD, Thomas S, Przytulinska M, Johnson EF, Klinghofer V, et al. Isoxazolo[3,4-b]quinoline-3,4(1H, 9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim- 2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett. 2008;18:5206-8.
21. Warnecke-Eberz U, Bollschweiler E, Drebber U, Metzger R, Baldus SE, Holscher AH, et al. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 2009;29:4451-5.
22. Chen CN, Lin JJ, Chen JJ, Lee PH, Yang CY, Kuo ML, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol. 2005;23:7286-95. (Pubitemid 46202342)
23. Nagarajan L, Louie E, Tsujimoto Y, ar-Rushdi A, Huebner K, Croce CM. Localization of the human pim oncogene (PIM) to a region of chromosome 6 involved in translocations in acute leukemias. Proc Natl Acad Sci USA. 1986;83:2556-60. (Pubitemid 16026921)
24. Gorringe KL, Boussioutas A, Bowtell DD. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer. 2005;42:247-59. (Pubitemid 40171189)
25. Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther. 2010;9: 1188-97.
26. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493-8.
27. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYCdependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007;9:932-44. (Pubitemid 47190448)
28. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 2006;7:1.
29. Aho TL, Sandholm J, Peltola KJ, Ito Y, Koskinen PJ. Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity. BMC Cell Biol. 2006;7:21.
30. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta. 2002;1593:45-55. (Pubitemid 35335911)
31. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem. 2004;279:48319-28. (Pubitemid 39540988)
32. Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol. 2010;34:882-91.
33. Santio NM, Vahakoski RL, Rainio EM, Sandholm JA, Virtanen SS, Prudhomme M, et al. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer. 2010;9:279.
34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82. (Pubitemid 17231334)
35. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63:839-42.
36. Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res. 2005;3:170-81. (Pubitemid 40524900)